Title:
APPLICATION OF RIP2 INHIBITOR COMBINED WITH CHEMOTHERAPY DRUG
Document Type and Number:
WIPO Patent Application WO/2023/088356
Kind Code:
A1
Abstract:
An application of a receptor-interacting protein 2 (RIP2) inhibitor combined with a chemotherapy drug, particularly, an application of a RIP2 inhibitor combined with a chemotherapy drug in preparation of a drug for treating and/or preventing a tumor. For the first time, the RIP2 inhibitor is found to enhance the antitumor activity of chemotherapy drugs; after combined administration, the ratios of CD45+ cells, neutrophils, dendritic cells, macrophages, CD4+T cells, CD8+T cells, and γ/δT cells in the tumor microenvironment are up-regulated, and tumor chemotherapy resistance is reversed.
Inventors:
LIU GANG (CN)
MA YAO (CN)
WEI XIDUAN (CN)
MA YAO (CN)
WEI XIDUAN (CN)
Application Number:
PCT/CN2022/132514
Publication Date:
May 25, 2023
Filing Date:
November 17, 2022
Export Citation:
Assignee:
NINGBO COMBIREG PHARMACEUTICAL TECH CO LTD (CN)
International Classes:
A61K45/06; A61K31/337; A61P35/00
Foreign References:
| CN109310768A | 2019-02-05 | |||
| CN111789952A | 2020-10-20 | |||
| CN109420170A | 2019-03-05 | |||
| CN1743006A | 2006-03-08 | |||
| CN109528720A | 2019-03-29 |
Other References:
JAAFAR ROLA, MNICH KATARZYNA, DOLAN SARAH, HILLIS JENNIFER, ALMANZA AITOR, LOGUE SUSAN E., SAMALI AFSHIN, GORMAN ADRIENNE M.: "RIP2 enhances cell survival by activation of NF-ĸB in triple negative breast cancer cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 497, no. 1, 1 February 2018 (2018-02-01), Amsterdam NL , pages 115 - 121, XP093067358, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2018.02.034
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: